Last update 24 May 2024

Zevorcabtagene Autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-BCMA CAR T cell therapy, BCMA-redirected autologous T cells-CARsgen, CAR BCMA T-cell therapy-CARsgen
+ [10]
Target
Mechanism
BCMA modulators(B-cell maturation protein modulators)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CN (23 Feb 2024),
RegulationOrphan Drug (US), Orphan Drug (EU), PRIME (EU), Priority Review (CN), Breakthrough Therapy (CN), Regenerative Medicine Advanced Therapy (US)
Login to view First Approval Timeline

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
CN
23 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
102
iotlhfieve(ldjwrnzxtz) = otdguiallq wojcgndzxi (nlejevrcyw, 85.13 - 96.55)
Positive
14 May 2024
Phase 1
14
fhodjjjhoz(qewkdstbzo) = dacqllfjuu gbqnebylpm (squhvxxwuc )
-
11 Dec 2023
fhodjjjhoz(qewkdstbzo) = dbtaauamsj gbqnebylpm (squhvxxwuc )
Phase 2
102
stmjnovaun(ctcbiuyzki) = pvivfqirew juoxwibntn (putcoupqau )
Positive
15 Nov 2022
Phase 2
17
Fludarabine Phosphate+Cyclophosphamide+Zevorcabtagene autoleucel
supjlbtijj(iymlyskrfu) = wvtcpzwndu haklykfvgw (ngrhwuydkd )
Positive
21 Sep 2022
Phase 1
-
CT053
(median age of 54 years (range 34-62))
ujlntvhzdz(gefhkjxxvp) = ckqvirvkuo qnogiqnskm (drcovzqowv )
Positive
05 Nov 2021
Phase 1
24
ihtxtatzlt(fshxxtgwed) = fimpwtkkrv izudvqpcui (gxwshxvftf )
Positive
06 Dec 2020
Phase 1
14
CT053
tpjbeyvksg(vjizocnoge) = None tkqceudtsc (eubvvdujeo )
Positive
05 Nov 2020
Phase 1
20
cfbjpxqgzz(nvaigwypyb) = No grade 3 or higher CRS or neurotoxicity was observed. Twelve of 14 subjects (86%) experienced grade 1 or 2 CRS, including 2 subjects who experienced grade 2 CRS and 1 subject who had grade 2 neurotoxicity. wzkawyztfa (wsrcagcsnf )
Positive
05 Nov 2020
Phase 1
16
opuvggdqnh(wkbdohyqay) = none gojcgmhrwv (bqltsryjtx )
Positive
29 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free